These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 34106410)
1. Leiomyoma and Leiomyosarcoma (Primary and Metastatic) of the Oral and Maxillofacial Region: A Clinicopathological and Immunohistochemical Study of 27 Cases. de Araújo GR; Costa SFDS; Mesquita RA; Gomez RS; Dos Santos JN; Pontes HAR; de Andrade BAB; Romañach MJ; Agostini M; Vargas PA; de Cáceres CVBL; Santos-Silva AR; Ribeiro ACP; Brandão TB; Tomasi RA; Ferreyra RS; de Almeida OP; Fonseca FP Head Neck Pathol; 2022 Mar; 16(1):294-303. PubMed ID: 34106410 [TBL] [Abstract][Full Text] [Related]
2. Uterine smooth muscle tumours with hyperintense area on T Ando T; Kato H; Furui T; Morishige KI; Goshima S; Matsuo M Br J Radiol; 2018 Apr; 91(1084):20170767. PubMed ID: 29308922 [TBL] [Abstract][Full Text] [Related]
3. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas. Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921 [TBL] [Abstract][Full Text] [Related]
4. Value of counting positive PHH3 cells in the diagnosis of uterine smooth muscle tumors. Pang SJ; Li CC; Shen Y; Liu YZ; Shi YQ; Liu YX Int J Clin Exp Pathol; 2015; 8(5):4418-26. PubMed ID: 26191133 [TBL] [Abstract][Full Text] [Related]
5. MVP immunohistochemistry is a useful adjunct in distinguishing leiomyosarcoma from leiomyoma and leiomyoma with bizarre nuclei. Lintel NJ; Luebker SA; Lele SM; Koepsell SA Hum Pathol; 2018 Mar; 73():122-127. PubMed ID: 29307622 [TBL] [Abstract][Full Text] [Related]
6. Uterine Leiomyosarcoma Associated With Leiomyoma With Bizarre Nuclei: Histology and Genomic Analysis of 2 Cases. Fischer JV; Mejia-Bautista M; Vadasz B; Yin P; Bulun S; Tanner EJ; Lu X; Wei JJ Int J Gynecol Pathol; 2022 Nov; 41(6):552-565. PubMed ID: 35093974 [TBL] [Abstract][Full Text] [Related]
7. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma. Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039 [TBL] [Abstract][Full Text] [Related]
9. Fascin expression in uterine smooth muscle tumors. Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633 [TBL] [Abstract][Full Text] [Related]
10. Integrated histologic and molecular analysis of uterine leiomyosarcoma and 2 benign variants with nuclear atypia. Gao T; Finkelman BS; Ban Y; Li Y; Yin P; Bulun SE; Lu X; Ha C; Wei JJ Cancer Sci; 2021 May; 112(5):2046-2059. PubMed ID: 33338329 [TBL] [Abstract][Full Text] [Related]
11. Use of X-chromosome inactivation pattern to determine the clonal origins of uterine leiomyoma and leiomyosarcoma. Zhang P; Zhang C; Hao J; Sung CJ; Quddus MR; Steinhoff MM; Lawrence WD Hum Pathol; 2006 Oct; 37(10):1350-6. PubMed ID: 16949924 [TBL] [Abstract][Full Text] [Related]
12. Pleomorphic Undifferentiated Uterine Sarcoma in a Young Patient Presenting With Elevated Beta-hCG and Rare Variants of Benign Leiomyoma: A Case Report and Review of the Literature. Krishnan V; Sauthier P; Provencher D; Rahimi K Int J Gynecol Pathol; 2020 Jul; 39(4):362-366. PubMed ID: 31033798 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Chen L; Yang B Int J Gynecol Pathol; 2008 Jul; 27(3):326-32. PubMed ID: 18580309 [TBL] [Abstract][Full Text] [Related]
14. Potential diagnostic biomarkers: differential expression of LMP2/β1i and cyclin B1 in human uterine leiomyosarcoma. Hayashi T; Horiuchi A; Sano K; Hiraoka N; Ichimura T; Sudo T; Ishiko O; Yaegashi N; Aburatani H; Konishi I Tumori; 2014; 100(4):99e-106e. PubMed ID: 25296613 [TBL] [Abstract][Full Text] [Related]
16. Uterine leiomyoma versus leiomyosarcoma: a new attempt at differential diagnosis based on their cellular characteristics. Watanabe K; Suzuki T Histopathology; 2006 Apr; 48(5):563-8. PubMed ID: 16623782 [TBL] [Abstract][Full Text] [Related]
17. Immunoexpression of progesterone receptor, epithelial growth factor receptor and galectin-3 in uterine smooth muscle tumors. Soltan MM; Albasry AM; Eldosouky MK; Abdelhamid HS Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):7-12. PubMed ID: 29729689 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors. Hewedi IH; Radwan NA; Shash LS Diagn Pathol; 2012 Jan; 7():1. PubMed ID: 22217299 [TBL] [Abstract][Full Text] [Related]
19. Differential Immunoreactivity of p16 in leiomyosarcomas and leiomyoma variants. Gannon BR; Manduch M; Childs TJ Int J Gynecol Pathol; 2008 Jan; 27(1):68-73. PubMed ID: 18156978 [TBL] [Abstract][Full Text] [Related]
20. Use of oxytocin receptor expression in distinguishing between uterine smooth muscle tumors and endometrial stromal sarcoma. Loddenkemper C; Mechsner S; Foss HD; Dallenbach FE; Anagnostopoulos I; Ebert AD; Stein H Am J Surg Pathol; 2003 Nov; 27(11):1458-62. PubMed ID: 14576480 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]